PureTech Health plc (LON:PRTC – Get Free Report)’s share price crossed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of GBX 122.95 and traded as low as GBX 120. PureTech Health shares last traded at GBX 120.40, with a volume of 10,714,180 shares.
PureTech Health Stock Down 2.9%
The company has a market capitalization of £295.20 million, a PE ratio of -2.34 and a beta of 0.77. The company’s 50 day moving average is GBX 116.81 and its two-hundred day moving average is GBX 122.95. The company has a quick ratio of 2.51, a current ratio of 4.60 and a debt-to-equity ratio of 4.78.
About PureTech Health
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.
Featured Stories
- Five stocks we like better than PureTech Health
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.
